Golimumab Clinical Trials

2 actively recruiting trials across 2 locations

No change since May 2026

Also known as: CNTO 148, Immunoglobulin G1, Anti-(Human Tumor Necrosis Factor Alpha) (Human Monoclonal CNTO 148 Gamma-1-Chain), Disulfide with Human Monoclonal CNTO 148 Kappa-Chain, Dimer, Simponi

Pipeline

Phase 3: 2

Top Sponsors

University of Pennsylvania1
University of Nebraska1

Indications

Arthritis2
Psoriatic Arthritis1
Rheumatoid Arthritis1

Loxahatchee Groves, Florida1 trial

Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

Family Arthritis Center

Phase 3

Omaha, Nebraska1 trial

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

University of Nebraska Medical Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.